Tropifexor

Tropifexor is a drug that is currently under investigation for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). It is a farnesoid X receptor (FXR) agonist, which means it activates the FXR, a nuclear receptor that plays a crucial role in regulating bile acids, lipids, and glucose homeostasis.

Mechanism of Action

Tropifexor works by activating the farnesoid X receptor (FXR). This receptor is found in the liver, kidney, adrenal gland, and intestine, and it plays a key role in regulating bile acids, lipids, and glucose. When activated, the FXR can help to reduce the amount of fat and inflammation in the liver, which can be beneficial for people with conditions like NASH and PBC.

Clinical Trials

Tropifexor is currently in the clinical trial phase for the treatment of NASH and PBC. Early results from these trials have shown promise, with patients experiencing a reduction in liver fat and inflammation. However, more research is needed to fully understand the drug's efficacy and safety profile.

Side Effects

As with any drug, Tropifexor may cause side effects. These can include nausea, vomiting, diarrhea, and abdominal pain. It's important for patients to discuss these potential side effects with their healthcare provider before starting treatment.

See Also

• Non-alcoholic steatohepatitis
• Primary biliary cholangitis
• Farnesoid X receptor
• Clinical trial

Tropifexor Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski